Wegovy oral tablets launched in UK with high initial demand
This story involves financial misconduct allegations. Any claims of wrongdoing described here are allegations, not established facts, unless a court or official body has ruled otherwise. This disclosure does not remove our responsibility for what's published below.
See sources Request a correction Report a serious problem / request takedown Corrections & takedown policy
AI-assisted synthesis, reviewed and approved by the editorial team. Generated , updated since first publication on as new sources were added. Approved by editorial team: .
The first GLP-1 weight-loss pill became available for purchase at some UK pharmacies starting in early July. High levels of demand are expected to result in potential delays for patients seeking the medication through the National Health Service.
Amalgamated from The Sun (opens in new tab), The Sun (opens in new tab), The Sun (opens in new tab), The Mirror (opens in new tab)
The Wegovy oral tablet, a member of the GLP-1 class of medications, is now available for sale in the United Kingdom. Reports from The Sun indicate that the pill is priced at approximately £25 per week when purchased through certain online pharmacies.
According to The Mirror, this marks the introduction of the first GLP-1 weight-loss tablet in the UK market. The publication reports that the medication serves as an alternative for patients who prefer a daily oral treatment over weekly injections.
Initial demand and availability
Evidence of high consumer interest emerged immediately upon the product's release. The Sun reported that more than 7,000 people ordered Wegovy pills through Asda pharmacies on the first day of sale. Faye Breckons, the healthcare director for the chain, stated that the company received over 13,000 inquiries regarding the new medication during that period.
Impact on public health services
The surge in demand is expected to create logistical challenges for the National Health Service (NHS). While the product is available for private purchase at a set cost, The Sun reports that millions of patients who rely on the NHS may face delays in accessing the medication. These delays are attributed by reports to the high volume of demand following the launch of the oral alternative.
Why this matters
The introduction of an oral GLP-1 medication marks a significant shift in how weight management drugs are administered. The transition from injections to pills may increase accessibility for some patients while simultaneously straining public healthcare infrastructure due to high demand.
What's confirmed / what isn't
Multiple sources confirm the launch of the Wegovy pill in the UK and its availability for private purchase at approximately £25 per week. The specific figures regarding Asda's inquiry volume and order numbers are reported by *The Sun*. The potential for significant delays within the NHS system is reported as a likely outcome of high demand.
Background
GLP-1 (glucagon-like peptide-1) medications are used to treat obesity and type 2 diabetes by mimicking a hormone that regulates blood sugar and appetite. Wegovy is a specific brand of this medication originally administered via injection.